



Form PTO-1449

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
0283-0178PAPPLICATION NO.  
10/664,165APPLICANT  
IMAIZUMI et al.FILING DATE  
September 17, 2003GROUP  
Unassigned**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						

**FOREIGN PATENT DOCUMENTS**

Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO

**OTHER DOCUMENTS**

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

"Maxikdiol: A Novel Dihydroxyisoprimane as an Agonist of Maxi-K Channels", Sheo B. Singh, et al., J. Chem. Soc. Perkin Trans. 1, 1994, p. 3349-3352.

"Molecular Basis of Pimarane Compounds as Novel Activators of Large-Conductance Ca<sup>2+</sup>-Activated K<sup>+</sup> Channel  $\alpha$ -Subunit", Yuji IMAIZUMI et al., Molecular Pharmacology, Vol. 62, p. 836-846 (2002).

"Dehydroabiatic Acid Derivatives as a Novel Scaffold for Large-Conductance Calcium-Activated K<sup>+</sup> Channel Openers", Tomohiko OHWADA et al., Bioorg. Med. Chem. Lett., 13 p. 3971-3974 (2003).

English translation of the International Preliminary Examination Report in PCT/JP02/04085.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered. Whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.